Dr. Paul, a distinguished figure in the field of immunology and vaccine development, has dedicated his career to advancing our understanding and protection against infectious diseases. His extensive body of work, spanning several decades, encompasses fundamental research on rotaviruses, innovative approaches to vaccine design, and crucial contributions to public health discussions surrounding vaccination. This bibliography serves as a testament to Dr. Paul’s profound impact, showcasing his prolific publications across esteemed scientific journals and public platforms. His research has not only deepened scientific knowledge but has also played a vital role in shaping global immunization strategies and addressing vaccine-related concerns.
Key Research Areas of Doctor Paul
Dr. Paul’s publications reveal a consistent focus on several critical areas within vaccine science. His pioneering work in rotavirus research is particularly notable, contributing significantly to the development and understanding of rotavirus vaccines, which have dramatically reduced childhood mortality worldwide. Beyond rotavirus, Dr. Paul has extensively explored the broader landscape of vaccine immunology, delving into the mechanisms of immune response to vaccines, and addressing crucial questions about vaccine safety and efficacy. His commitment to public health is evident through his publications that tackle vaccine hesitancy, advocate for evidence-based immunization policies, and communicate complex scientific information to a wider audience.
Pioneering Rotavirus Vaccine Development
A significant portion of Dr. Paul’s research, as reflected in his publications, centers around rotaviruses, a leading cause of severe diarrhea in infants and young children globally. His early work laid the groundwork for understanding the immune responses to rotavirus infection and the development of effective vaccines. Publications like the 2006 New England Journal of Medicine paper on the safety and efficacy of the pentavalent human-bovine rotavirus vaccine, co-authored by Dr. Paul, highlight his pivotal role in bringing life-saving vaccines to fruition. His research delves into various aspects of rotavirus vaccines, from evaluating their potency and composition to understanding the nuances of infant immune responses, as demonstrated in publications in journals like Vaccine and Journal of Pediatrics.
Contributions to Vaccine Safety and Public Health Discourse
Dr. Paul has consistently engaged in public discussions surrounding vaccine safety and the importance of immunization. His publications in outlets like Scientific American, The Philadelphia Inquirer, and Skeptical Inquirer showcase his commitment to dispelling misinformation and promoting science-based understanding of vaccines. Articles such as “Vaccines Do Not Cause Autism” in Scientific American and commentaries addressing “science denialism” directly confront public concerns and reinforce the scientific consensus on vaccine safety. Furthermore, Dr. Paul’s work extends to the policy realm, as seen in his Science publication advocating for vaccine mandates, underscoring his dedication to leveraging scientific evidence for effective public health strategies.
Advancements in Vaccine Immunology and Delivery
Beyond specific diseases, Dr. Paul’s research explores fundamental aspects of vaccine immunology. His publications in journals like Journal of Virology and Journal of Immunology delve into the intricacies of immune cell responses to vaccination, including cytotoxic T lymphocytes and memory B cells. He has investigated novel vaccine delivery systems, such as microencapsulation, aimed at enhancing vaccine immunogenicity, as evidenced by publications in Vaccine and Journal of Infectious Diseases. This body of work contributes to a deeper understanding of how vaccines elicit protective immunity and paves the way for the development of improved and innovative vaccination approaches.
Selected Publications by Doctor Paul
This section highlights a selection of Dr. Paul’s publications, demonstrating the breadth and depth of his contributions over the years.
Key Publications from the 2000s:
- 2006, N. Engl. J. Med 354:13-23: Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Gouveia MG, Black SB, Shinefield HR, Christie C, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O’Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM. Safety and efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine in preventing rotavirus gastroenteritis and associated healthcare contacts. – This landmark paper demonstrated the significant impact of the pentavalent rotavirus vaccine in preventing rotavirus disease.
- 2005, Health Affairs Journal, 24:622-630: Offit, P.A. Why are pharmaceutical companies gradually abandoning vaccines? – Dr. Paul addresses the economic challenges in vaccine development and manufacturing, raising important questions about public health and pharmaceutical industry incentives.
- 2003, Pediatrics 112:1394-1401: Offit, P.A., Jew, R.K. Addressing parents’ concerns: Do vaccines contain harmful preservatives, adjuvants, additives, or residuals? – This publication directly tackles parental anxieties about vaccine components, providing evidence-based reassurance and promoting informed decision-making.
Landmark Papers from the 1990s:
- 1999, J. Immunol. 163:3064-3070: Coffin, S.E., Clark, S.A., Bos, N.A., Brubaker, J.O., and Offit, P.A. Migration of antigen-presenting B cells from peripheral to mucosal lymphoid tissues may induce intestinal antigen-specific IgA following parenteral immunization. – This research explores the mechanisms of immune response to vaccines, focusing on the role of B cells in mucosal immunity.
- 1991, Virology 184:563-568: Offit, P.A., D.B. Boyle, G.W. Both, N.L. Hill, Y.M. Svoboda, S.L. Cunningham, R.J. Jenkins, and M.A. McCrae. Surface glycoprotein vp7 is recognized by crossreactive rotavirus-specific cytotoxic T lymphocytes. – This study investigates the cellular immune response to rotavirus, identifying key viral proteins recognized by cytotoxic T lymphocytes.
- 1990, J. Virol. 64:6325-6328: Offit, P.A. and K.I. Dudzik. Rotavirus-specific cytotoxic T lymphocytes passively protect against gastroenteritis in suckling mice. – This early work demonstrated the protective role of cytotoxic T lymphocytes in rotavirus infection, contributing to the understanding of immune mechanisms against rotaviruses.
Early Research in the 1980s:
- 1986, J. Virol. 60: 491-496: Offit, P.A., G. Blavat, H.F. Clark, and H.B. Greenberg. Reassortant rotaviruses containing structural proteins vp3 and vp7 from different parents induce antibodies protective against each parental serotype. – This publication explores the genetic basis of rotavirus neutralization and the potential for developing broadly protective vaccines.
- 1985, J. Infect. Dis. 152: 1152-1158: Offit, P.A., and H.F. Clark. Maternal antibody-mediated protection against gastroenteritis due to rotavirus in neonatal mice is dependent on both serotype and titer of antibody. – This study investigates the role of maternal antibodies in protecting newborns against rotavirus infection, highlighting factors influencing passive immunity.
- 1983, J. Virol. Methods 7: 29-40: Offit, P.A., H.F. Clark, W.G. Stroop, E.M. Twist, and S.A. Plotkin. The cultivation of human rotavirus, strain ‘WA’, to high titer in cell culture and characterization of the viral structural polypeptides. – This methodological paper describes advancements in culturing human rotavirus, essential for vaccine development and further research.
Complete Bibliography of Doctor Paul
2018
Plotkin, S.A., P.A. Offit, and P. Bégué: “Vaccine mandates in France will save lives,” Science 359: 283-284, 2018.
Plotkin SA, Offit PA, Reiss D.: Important New Resource for Clinicians Giving Expert Witness Testimony on Vaccines. Pediatr Infect Dis J. 37(12), Dec. 2018.
Offit, P.A.: Challenges to developing a rotavirus vaccine In Viral Immunology 31(2), March 2018.
Offit PA.: Challenges to Developing a Rotavirus Vaccine. Viral Immunol. 31(2): 104-108, Mar. 2018.
2017
Offit, P.A.: “God’s Own Medicine,” Skeptical Inquirer 41: 44-45, 2017.
Offit, P.A.: “Vaccines Do Not Cause Autism,” Scientific American, Special Edition Page: 22, Winter 2017/2017 2017.
Offit, P.A.: “The First Smallpox Vaccine Wasn’t What We Thought It Was,” The Daily Beast December 4 2017.
Offit, P.A.: “Commentary: Science Denialism Isn’t New to the Trump Administration,” Philadelphia Inquirer December 22 2017.
Offit, P.A.: “By Regulating Homeopathic Remedies, FDA Holds ‘Modern-Day Snake-Oil Salesmen’ Accountable,” Philadelphia Inquirer December 28 2017.
Katsuta T, Miyaji Y, Offit PA, Feemster KA. Treatment with quadrivalent human papillomavirus vaccine for juvenile-onset recurrent respiratory papillomatosis: case report and review of the literature. J Pedatr Infect Dis Soc 2017; doi:10.1093/jpids/pix063
Handy L, Maroudi S, Powell M, Nfila B, Moser C, Japa I, Monyatsi N, Tzortzi E, Kouzeli I, Luberti A, Theodoridou M, Offit P, Steenhoff A, Shea JA, Feemster KA. 2017. The impact of access to immunization information on vaccine acceptance in three countries. PLOS One.
2013
Williams SE, Rothman RL, Offit PA. Schaffner W, Sullivan M, Edwards KM. A randomized trial to increase acceptance of childhood vaccines by vaccine-hesitant parents: a pilot study. Academic Pediatrics (2013) 13: 475-480.
2011
Feemster KA, Prasad P., Smith MJ, Feudtner C, Caplan A, Offit PA, Coffin SE. 2011. Health care worker support of an influenza vaccine mandate at a large pediatric tertiary care hospital. Vaccine 29: 1762-1769.
2006
Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG, Ward RL, Schödel F, Karvonen A, DiNubile MJ, Heaton PM. 2006. Effects of potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 24:4821-4829.
Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Gouveia MG, Black SB, Shinefield HR, Christie C, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O’Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM. 2006. Safety and efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine in preventing rotavirus gastroenteritis and associated healthcare contacts. N. Engl. J. Med 354:13-23.
2005
Offit, P.A. 2005. The Cutter Incident, 50 years later. N. Engl. J. Med. 352:1411-1412.
Offit, P.A. 2005. Why are pharmaceutical companies gradually abandoning vaccines? Health Affairs Journal, 24:622-630.
2004
Clark HF, Bernstein DI, Dennehy P, Offit P, Pichichero M, Treanor J, Ward RL, Krah DL, Shaw A, Dallas MJ, Eiden JJ, Ivanoff N, Kaplan KM, Heaton P. 2004. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J. Pediatr. 144:184-190.
Clark HF, Lawley D, Shrager D, Jean-Guillaume D, Offit P, Eiden JJ, Bennett PS, Kaplan, KM, Shaw A. 2004. Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant WI79-9: Different dose response patterns to virus surface proteins vp7 and vp4. Pediatr. Infect. Dis. J. 23:206-211.
2003
Clark HF, Burke CJ, Volkin DV, Offit, P, Ward RL, Breese JS, Dennehy P, Gooch WM, Malacaman E, Matson D, Walter E, Watson B, Krah DL, Dallas MJ, Schödel F, Kaplan KM, Heaton P. 2003. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatr. Infect. Dis. J. 22:914-920.
Offit, P.A. and Peter G. 2003. The meningococcal vaccine: public policy and individual choices. N. Engl. J. Med. 349:2353-2356; Offit, P.A., Peter, G. Choices about meningococcal vaccine. [correspondence] N. Engl. J. Med. 2004;350:1156.
Offit, P.A. and Coffin, S.E. 2003. Communicating science to the public: MMR vaccine and autism. Vaccine 22:1-6.
Offit, P.A., Jew, R.K. 2003. Addressing parents’ concerns: Do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics 112:1394-1401.
Chow, A.A., Moser C.A., Speaker, T.J., and Offit, P.A. 2003. Determination of efficiency of attachment of biotinylated antibodies to avidin-linked, aqueous-based microcapsules by flow cytometry. J. Immunol. Methods 2003;277:135-139.
Offit, P.A. and Hackett, C.J. 2003. Addressing parents’ concerns: Do vaccines cause allergic or autoimmune diseases? Pediatrics 111:653-659.
2002
Offit, P.A., Gerber, M.A., Hackett, C., Marcuse, E., and Gellin, B. 2002. Too many vaccines? (correspondence). Pediatrics 110:649.
Offit, P.A., Quarles, J., Gerber, M.A., Hackett, C.J., Marcuse, E.K., Kollman, T.R., Gellin, B.G., and Landry, S. 2002. Addressing parents’ concerns: Do multiple vaccines overwhelm or weaken the infant’s immune system? Pediatrics 109:124-129.
Brubaker, J.O., K.K. Macartney, T.J. Speaker, and P.A. Offit. 2002. Specific attachment of covalently modified aqueous-based microcapsules to macrophages, B cells, and dendritic cells. J. Microencapsulation 19:213-223.
2001
Moser, C.A. and P.A. Offit. 2001. Distribution of rotavirus-specific memory B cells in gut-associated lymphoid tissue after primary immunization. J. Gen. Virol. 82:2271-2274.
Clark, HF, D. Lawley, D. Shrager, D. Jean-Guillaume, P.A. Offit, J. Eiden, and A.R. Shaw. 2001. Immune response of infants to bovine human rotavirus serotype G1 reassortant WI79-9: the dose response pattern to virus surface protein vp7 differs from that to vp4. Pediatr Infect Dis J. 2004 Mar;23(3):206-11.
Kushnir, N., N.A. Bos, A.W. Zuercher, S.E. Coffin, C.A. Moser, P.A. Offit, and J.J. Cebra. 2001. B2 but not B1 B cells can contribute to CD4+ T cell-mediated clearance of rotavirus in SCID mice. J. Virol. 75:5482-5490.
Moser, C.A., D.V. Dolfi, M.L. DiVietro, P.A. Offit, and H F. Clark. 2001. Hypertrophy, hyperplasia, and infectious virus in gut-associated lymphoid tissue of mice after oral inoculation with simian-human or bovine-human reassortant rotaviruses. J. Infect. Dis. 183:1108-1111.
2000
Brown, K.A., J.A. Kriss, C.A. Moser, W.J. Wenner, and P.A. Offit. 2000. Circulating rotavirus-specific antibody-secreting cells (ASC) predict the presence of rotavirus-specific ASC in the human small intestinal lamina propria. J. Infect. Dis. 182:1039-1043.
Macartney, K.M., D. Baumgart, S.R. Carding, J.O. Brubaker, and P.A. Offit. 2000. Primary murine small intestinal epithelial cells, maintained in long-term culture, are susceptible to rotavirus infection. J. Virol. 74:5597-5603.
Brubaker, J., R. Patel, T.J. Speaker, and P.A. Offit. 2000. A quantitative luminescence assay for measuring cell uptake of aqueous-based microcapsules in vitro. J. Immunol. Methods 237:85-93.
1999
Coffin, S.E., Moser, C.A., Cohen, S., Speaker, T.J., and Offit, P.A. 1999. Viral microencapsulation delays protection after intramuscular inoculation of mice with rotavirus. Drug Delivery 6:253-257.
Coffin, S.E., Clark, S.A., Bos, N.A., Brubaker, J.O., and Offit, P.A. 1999. Migration of antigen-presenting B cells from peripheral to mucosal lymphoid tissues may induce intestinal antigen-specific IgA following parenteral immunization. J. Immunol. 163:3064-3070.
1998
Moser, C.A., Speaker, T.J., and Offit, P.A. 1998. Effect of water-based microencapsulation on protection against EDIM rotavirus challenge in mice. J. Virol. 72:3859-3862.
Coffin, S.E., and Offit, P.A. 1998. Induction of rotavirus-specific memory B cells in gut-associated lymphoid tissue after intramuscular immunization. J. Virol. 72:3479-3483.
Brown, K.A. and Offit, P.A. 1998. Rotavirus-specific proteins are detected in murine macrophages in both intestinal and extraintestinal lymphoid tissue. Microbial Pathogen. 24:327-331.
Moser, C.A., Coffin, S.E., Cookinham, S., and Offit, P.A. 1998. Relative importance of rotavirus-specific effector and memory B cell responses in protection against challenge. J. Virol. 72:1108-1114.
1997
Coffin, S.E., Moser, C.A., Cohen, S., Clark, HF., and Offit, P.A. 1997. Immunologic correlates of protection against challenge after intramuscular immunization of mice with rotavirus. J. Virol. 71:7851-7856.
Moser, C.A., Speaker, T.J., and Offit, P.A. 1997. Effect of microencapsulation on immunogenicity of a bovine herpes virus glycoprotein and inactivated influenza virus in mice. Vaccine 15: 1767-1772.
Lomotan, E.A., Brown, K.A., Speaker, T.J., and Offit, P.A. 1997. Aqueous-based microcapsules are detected primarily in gut-associated dendritic cells after oral inoculation of mice. Vaccine 15:1959-1962.
1996
Moser, C.A., Speaker, T.J., Berlin, J.A., and Offit, P.A. 1996. Aqueous-based microencapsulation enhances rotavirus-specific humoral immune responses after parenteral inoculation of mice. Vaccine 14:1235-1238.
1995
Coffin, S.E., Klinek, M., and Offit, P.A. 1995. Induction of virus-specific antibody production by lamina propria lymphocytes following intramuscular inoculation with rotavirus. J. Infect. Dis. 172: 874-878.
Khoury, C.A., Moser, C.A., Speaker, T.J., and Offit, P.A. 1995. Oral inoculation of mice with low doses of microencapsulated, noninfectious rotavirus induces virus-specific antibodies in gut-associated lymphoid tissue. J. Infect. Dis. 172: 870-874.
Brown, K.A., Moser, C.A., Khoury, C.A., Kim, J.E., and P.A. Offit. 1995. Enhancement by microencapsulation of rotavirus-specific intestinal immune responses in mice assessed by enzyme-linked immunospot assay and intestinal fragment culture. J. Infect. Dis. 171:1334-1338.
Treanor, J.J., Clark, HF., Pichichero, M., Christy, C., Gouvea, V., Shrager, D., Pallazo, S., and Offit, P.A. 1995. Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants. Pediatr. Infect. Dis. J. 14:301-307.
1994
Khoury, C.A., Brown, K., Kim, J., and Offit, P.A.. 1994. Rotavirus-specific intestinal immune response in mice assessed by enzyme-linked immunospot assay and intestinal fragment culture. Clin. Diag. Lab. Immunol. 1:722-728.
Offit, P.A., Khoury, C.A., Moser, C.H., Clark, HF., and Speaker T.J. 1994. Enhancement of rotavirus immunogenicity by microencapsulation. Virology 203:134-143.
Santos, N., Riepenhoff-Talty, M., Clark, H.F., Offit, P, and Gouvea, V. 1994. Vp4 genotyping of human rotavirus in the USA. J. Clin. Microbiol. 32:205-208.
Offit, P.A., B.E.H. Coupar, Y. M. Svoboda, R.J. Jenkins, M.A. McRae, A. Abraham, N.L. Hill, D.B. Boyle, and G.W. Both. 1994. Induction of rotavirus-specific cytotoxic T lymphocytes by vaccinia virus recombinants expressing individual rotavirus genes. Virology 198:10-16.
1993
Christy, C., P.A. Offit, H F. Clark, and J. Treanor. 1993. Evaluation of a bovine-human rotavirus reassortant vaccine in infants. J. Infect. Dis. 168:1598-1599.
Offit, P.A., E.J. Hoffenberg, N. Santos, and V. Gouvea. 1993. Rotavirus-specific humoral and cellular immune response after primary, symptomatic infection. J. Infect. Dis. 167:1436-1440.
1992
Ammari, L.K., P.A. Offit, A.B. Campbell. 1992. Unusual presentation of group B streptococcus osteomyelitis. Pediatr. Infect. Dis. J. 11:1066-1067.
Offit, P.A., E.J. Hoffenberg, E.S. Pia, P.A. Panackal, and N.L. Hill. 1992. Rotavirus-specific helper T cell response in newborns, infants, children, and adults. J. Infect. Dis. 165:1107-1111.
Nadel, S., P.A. Offit, R. Hodinka, R. Gesser, and L.M. Bell. 1992. Upper airway obstruction in perinatally-acquired herpes simplex virus infection. J. Pediatr. 120:127-129.
1991
Brussow, H., P.A. Offit, J. Sidoti. 1991. Neutralizing antibodies to heterologous animal rotavirus serotypes 5, 6, 7, and 10 in sera from Ecuadorian children. J. Clin. Microbiol. 29:869-873.
Offit, P.A., D.B. Boyle, G.W. Both, N.L. Hill, Y.M. Svoboda, S.L. Cunningham, R.J. Jenkins, and M.A. McCrae. 1991. Surface glycoprotein vp7 is recognized by crossreactive rotavirus-specific cytotoxic T lymphocytes. Virology 184:563-568.
Offit, P.A., S.L. Cunningham, and K.I. Dudzik. 1991. Memory and distribution of virus-specific cytotoxic T lymphocytes (CTLs) and CTLp after rotavirus infection. J. Virol. 65:1318-1324.
Offit, P.A. and K.I. Dudzik. 1990. Rotavirus-specific cytotoxic T lymphocytes passively protect against gastroenteritis in suckling mice. J. Virol. 64:6325-6328.
1990
Matsuda Y., O. Nakagomi, and P.A. Offit. 1990. Presence of three P types (vp4 serotypes) and two G types (vp7 serotypes) among bovine rotavirus strains. Arch. Virol. 115:199-207.
Brussow H., P.A. Offit, G. Gerna, A. Bruttin, and J. Sidoti. 1990. Polypeptide specificity of anti-viral serum antibodies in children naturally infected with human rotavirus. J. Virol. 64:4130-4136.
1989
Offit, P.A. and Y.M. Svoboda. 1989. Rotavirus-specific cytotoxic T lymphocyte response of mice after oral inoculation with candidate rotavirus vaccine strains RRV or WC3. J. Infect. Dis. 160:783-788.
Offit, P.A., H.B. Greenberg, and K.I. Dudzik. 1989. Rotavirus-specific protein synthesis is not necessary for recognition of infected cells by virus-specific cytotoxic T lymphocytes. J. Virol. 63: 3279-3283.
Offit, P.A., and K.I. Dudzik. 1989. Rotavirus-specific cytotoxic T lymphocytes appear at the intestinal mucosal surface after rotavirus infection. J. Virol. 63: 3507-3512.
Matsui, S., P.A. Offit, P.T. Vo, E.R. Mackow, D.A. Benfield, R.D. Shaw, L. Padilla-Noriega, and H.B. Greenberg. 1989. Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to the heterotypic neutralization domain of vp7 and the vp8 fragment of vp4. J. Clin. Microbiol. 27: 780-782.
Offit, P.A., and K.I. Dudzik. 1989. Noninfectious rotavirus (strain RRV) induces and immune response which protects against rotavirus challenge. J. Clin. Microbiol. 27: 885-888.
Offit, P.A., and K.I. Dudzik. 1988. Rotavirus-specific cytotoxic T lymphocytes cross-react with target cells infected with different rotavirus serotypes. J. Virol. 62:127-131.
1988
Liu, M., P.A. Offit, and M.K. Estes. 1988. Identification of the simian rotavirus SA11 genome segment 3 product. Virology 163: 26-32.
1987
Clark, H.F., Y. Hoshino, L.M. Bell, J. Groff, P. Bachman, and P.A. Offit. 1987. A rotavirus isolate WI61 representing a presumptive new human serotype. J. Clin. Microbiol. 25: 1757-1762.
Bell, L.M., H.F. Clark, E.A. O’Brien, M.J. Kornstein, S.A. Plotkin, and P.A. Offit. 1987. Gastroenteritis caused by human rotaviruses (serotype 3) in a suckling mouse model. Proc. Soc. Exp. Biol. Med. 184: 127-132.
Bell, L.M., H.F. Clark, P.A. Offit, P.H. Slight, A.M. Arbeter, and S.A. Plotkin. 1987. Rotavirus serotype-specific neutralizing activity in human milk. Am. J. Dis. Child. 142: 275-278.
1986
Offit, P.A., G. Blavat, H.F. Clark, and H.B. Greenberg. 1986. Reassortant rotaviruses containing structural proteins vp3 and vp7 from different parents induce antibodies protective against each parental serotype. J. Virol. 60: 491-496.
Shaw, R.D., T.V. Phuoc, P.A. Offit, B.S. Coulson, and H.B. Greenberg. 1986. Antigenic mapping of the surface proteins of rhesus rotavirus. Virology 155: 434-451.
Clark, H.F., T. Furukawa, L.M. Bell, P.A. Offit, P.A. Parrella, and S.A. Plotkin. 1986. Immune response of infants and children to low-passage bovine rotavirus (strain WC-3). Am J. Dis. Child. 140:350-356.
Clark, H.F., P.A. Offit, K.T. Dolan, A. Tezza, K. Gogalin, E.M. Twist, and S.A. Plotkin. 1986. Response of adult human volunteers to oral administration of bovine and bovine/human reassortant rotaviruses. Vaccine 4: 25-31.
Offit, P.A., R. Shaw, and H.B. Greenberg. 1986. Protection against rotavirus-induced gastroenteritis in newborn mice by monoclonal antibodies to surface proteins vp3 and vp7. J. Virol. 58: 700-703.
Offit, P.A., and G. Blavat. 1986. Identification of the two rotavirus genes determining neutralization specificities. J. Virol. 57: 376-378.
10. Offit, P.A., G. Blavat, H.B. Greenberg, and H.F. Clark. 1986. Molecular basis of rotavirus virulence: role of gene segment 4. J. Virol. 57: 46-49.
1985
Clark, H.F., P.A. Offit, K. Dolan, T. Furukawa, L. Bell, and S.A. Plotkin. 1985. Rotavirus (RV) of bovine and human origin: immune response of adults and children following oral administration. Pediatr. Res. 19: 290 A.
Offit, P.A., and H.F. Clark. 1985. Maternal antibody-mediated protection against gastroenteritis due to rotavirus in neonatal mice is dependent on both serotype and titer of antibody. J. Infect. Dis. 152: 1152-1158.
Offit, P.A., and H.F. Clark. 1985. Protection against rotavirus-induced gastroenteritis in a murine model by passively-acquired gastrointestinal but not circulating antibodies. J. Virol. 54: 58-64.
1984
Offit, P.A., H.F. Clark, A.H. Taylor, R.G. Hess, P.A. Bachman, and S.A. Plotkin. 1984. Rotavirus-specific antibodies in fetal bovine serum and commercial preparations of serum albumin. J. Clin. Microbiol. 20: 266-270.
Offit, P.A., Clark, H.F., M. Kornstein, and S.A. Plotkin. 1984. A murine model for oral infection with a primate rotavirus (simian strain SA-11). J. Virol. 51: 233-236.
Offit, P.A., H.F. Clark, and S.A. Plotkin. 1983. Experimental analysis of the immune response to rotaviruses of bovine or primate origin assessed by radioimmunoassay, radioimmunoprecipitation, and plaque-reduction neutralization. Infect. Immun. 42: 293-300.
1983
Offit, P.A., H.F. Clark, W.G. Stroop, E.M. Twist, and S.A. Plotkin. 1983. The cultivation of human rotavirus, strain ‘WA’, to high titer in cell culture and characterization of the viral structural polypeptides. J. Virol. Methods 7: 29-40.
1982
Offit, P.A., S. Starr, P. Zolnick, and S.A. Plotkin. 1982. Acyclovir treatment in neonatal herpes simplex virus infection. Ped. Infect. Dis. 1: 253-255.
Offit, P.A., J. Campos, and S.A. Plotkin. 1982. Ampicillin-resistant, beta-lactamase negative, Haemophilus influenza type b. Pediatrics 69: 230-232.
1981
Offit, P.A., G.B. Fleischer, N. Koven, and S.A. Plotkin. 1981. Severe pneumonia in Epstein-Barr virus infection. J. Adol. Health Care 2: 121-125.
Conclusion
Dr. Paul’s bibliography represents a remarkable and enduring contribution to the scientific literature on vaccines and immunology. His work has been instrumental in advancing vaccine development, particularly in the field of rotavirus vaccines, and in shaping public health understanding and policy regarding immunization. This compilation of publications serves as a valuable resource for researchers, healthcare professionals, and anyone seeking to understand the scientific basis of vaccines and the impactful career of Doctor Paul.
